EE200300134A - Uued tiadiasoolid ja oksadiasoolid ning nende kasutamine fosfodiesteraas-7 inhibiitoritena - Google Patents

Uued tiadiasoolid ja oksadiasoolid ning nende kasutamine fosfodiesteraas-7 inhibiitoritena

Info

Publication number
EE200300134A
EE200300134A EEP200300134A EEP200300134A EE200300134A EE 200300134 A EE200300134 A EE 200300134A EE P200300134 A EEP200300134 A EE P200300134A EE P200300134 A EEP200300134 A EE P200300134A EE 200300134 A EE200300134 A EE 200300134A
Authority
EE
Estonia
Prior art keywords
oxadiazoles
phosphodiesterase
inhibitors
thiadiazoles
novel
Prior art date
Application number
EEP200300134A
Other languages
English (en)
Estonian (et)
Inventor
Vergne Fabrice
Ducrot Pierre
Andrianjara Charles
Bernardelli Patrick
Lorthiois Edwige
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of EE200300134A publication Critical patent/EE200300134A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/121,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/1251,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EEP200300134A 2000-10-02 2001-10-01 Uued tiadiasoolid ja oksadiasoolid ning nende kasutamine fosfodiesteraas-7 inhibiitoritena EE200300134A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00402710A EP1193261A1 (fr) 2000-10-02 2000-10-02 Thiadiazoles et leur utilisation comme inhibiteurs de phophodiestérase-7
PCT/EP2001/011330 WO2002028847A1 (fr) 2000-10-02 2001-10-01 Nouveaux thiadiazoles et oxadiazoles et utilisation de ceux-ci comme inhibiteurs de la phosphodiesterase de type 7

Publications (1)

Publication Number Publication Date
EE200300134A true EE200300134A (et) 2003-08-15

Family

ID=8173891

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300134A EE200300134A (et) 2000-10-02 2001-10-01 Uued tiadiasoolid ja oksadiasoolid ning nende kasutamine fosfodiesteraas-7 inhibiitoritena

Country Status (43)

Country Link
US (1) US7122565B2 (fr)
EP (2) EP1193261A1 (fr)
JP (1) JP4177098B2 (fr)
KR (1) KR100614158B1 (fr)
CN (1) CN1639141A (fr)
AP (1) AP1541A (fr)
AR (1) AR035347A1 (fr)
AT (1) ATE304003T1 (fr)
AU (2) AU2001289945B2 (fr)
BG (1) BG107654A (fr)
BR (1) BR0114391A (fr)
CA (1) CA2424279A1 (fr)
CZ (1) CZ2003857A3 (fr)
DE (1) DE60113283T2 (fr)
DK (1) DK1326853T3 (fr)
DZ (1) DZ3440A1 (fr)
EA (1) EA007179B1 (fr)
EC (1) ECSP034534A (fr)
EE (1) EE200300134A (fr)
ES (1) ES2247166T3 (fr)
GE (1) GEP20053459B (fr)
GT (1) GT200100196A (fr)
HN (1) HN2001000217A (fr)
HR (1) HRP20030247A2 (fr)
HU (1) HUP0301248A3 (fr)
IL (1) IL155122A0 (fr)
IS (1) IS6759A (fr)
MA (1) MA25916A1 (fr)
MX (1) MXPA03002839A (fr)
NO (1) NO20031482L (fr)
NZ (1) NZ524852A (fr)
OA (1) OA12518A (fr)
PA (1) PA8529501A1 (fr)
PE (1) PE20020419A1 (fr)
PL (1) PL366332A1 (fr)
PT (1) PT1326853E (fr)
SI (1) SI1326853T1 (fr)
SK (1) SK3812003A3 (fr)
SV (1) SV2003000633A (fr)
TN (1) TNSN01139A1 (fr)
WO (1) WO2002028847A1 (fr)
YU (1) YU24503A (fr)
ZA (1) ZA200302346B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004044235A1 (fr) * 2002-11-13 2004-05-27 Bayer Healthcare Ag Procedes de diagnostic de maladies associees a la phosphodiesterase 7a1 (pde7a1) humaine et moyens therapeutiques correspondants
ES2217956B1 (es) * 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
JP2006219374A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Pde7阻害作用を有するイミダゾトリアジノン誘導体
JP2006219373A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Pde7阻害作用を有するピリジニルピラゾロピリミジノン誘導体
AU2005258410B2 (en) 2004-07-01 2011-12-22 Daiichi Sankyo Company Limited Thienopyrazole derivative having PDE7 inhibitory activity
EP2258359A3 (fr) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenèse par modulation des récepteurs muscariniques avec sabcomeline
WO2007025177A2 (fr) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenese par modulation du recepteur muscarinique
EP1940389A2 (fr) 2005-10-21 2008-07-09 Braincells, Inc. Modulation de la neurogenese par inhibition de la pde
CA2625210A1 (fr) 2005-10-31 2007-05-10 Braincells, Inc. Modulation de la neurogenese dont la mediation est assuree par recepteur gaba
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2651813A1 (fr) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenese par modulation de l'angiotensine
WO2007134077A2 (fr) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenèse induite par le récepteur 5ht
JP2010502722A (ja) 2006-09-08 2010-01-28 ブレインセルス,インコーポレイティド 4−アシルアミノピリジン誘導体を含む組み合わせ
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
BRPI0809244A2 (pt) * 2007-03-27 2014-09-23 Omeros Corp Métodos de tratamento de uma anormalidade de movimento, e para identificação de um agente que inibe a atividade pde7.
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
MD3995C2 (ro) * 2009-05-11 2010-07-31 Государственный Университет Молд0 Utilizare a di(µ-Ofenoxi)-di{[2-(4-aminobenzensulfamido)-5-etil-1,3,4-tiadiazol]-3,5-dibromosalicilidentiosemicarbazonato(-1)-cupru} în calitate de inhibitor al proliferării celulelor T-47D ale cancerului mamar
US8703768B2 (en) 2010-06-09 2014-04-22 Hoffmann-La Roche Inc. Nitrogen containing heteroaryl compounds
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
KR102054899B1 (ko) 2010-11-08 2019-12-11 오메로스 코포레이션 Pde7 억제제를 사용한 중독 및 충동-조절 장애의 치료
CN102276625B (zh) * 2011-08-24 2013-07-17 天津药物研究院 噻二唑衍生物
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
CN103288777A (zh) * 2013-05-28 2013-09-11 浙江禾田化工有限公司 特丁噻草隆关键中间体2-甲基氨基-5-叔丁基-1,3,4-噻二唑的合成方法
US9416652B2 (en) 2013-08-08 2016-08-16 Vetco Gray Inc. Sensing magnetized portions of a wellhead system to monitor fatigue loading
SG10201911989SA (en) * 2015-06-12 2020-02-27 Oryzon Genomics Sa Biomarkers associated with lsd1 inhibitors and uses thereof
CN107674042B (zh) * 2017-09-28 2020-09-25 河南科技大学 一种超声波无溶剂合成噻二唑类化合物的方法
CN113480486B (zh) * 2021-07-30 2022-05-24 赣南师范大学 一种3-胺基-1,2,4-三唑类衍生物及其制备方法和应用
WO2024038089A1 (fr) 2022-08-18 2024-02-22 Mitodicure Gmbh Utilisation d'un agent thérapeutique ayant une activité inhibitrice de phosphodiestérase-7 pour le traitement et la prévention de maladies associées à la fatigue, à l'épuisement et/ou à l'intolérance à l'effort chroniques

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE251979C (fr)
FR2388806A1 (fr) 1977-04-25 1978-11-24 Gulf Oil Corp Nouvelles 3-benzyl-2-methylimino-5-phenyl4-1,3,4 thiadiazolines et leur application au desherbage chimique de cultures
DK270880A (da) 1979-07-09 1981-01-10 Gulf Oil Corp Phenyliminothiadiazolidiner deres fremstilling og anvendelse i plantevaekstregulerende midler
DD247003A1 (de) * 1985-11-07 1987-06-24 Hydrierwerk Rodleben Veb Verfahren zur herstellung von in 2-stellung mit amninhaltigen gruppen subst. 7 h-1,3,4-thiadiazolo(3,2-a)pyrimidinen
DD251979A1 (de) * 1986-08-01 1987-12-02 Neubauer T Paedagog Hochschule Verfahren zur herstellung von s-triazinylsubstituierten 2-imino-1,3,4-oxadiazolinen
DE4418066A1 (de) 1994-05-24 1995-11-30 Bayer Ag Substituierte Thiadiazoline
US6326378B1 (en) * 1998-02-17 2001-12-04 Roche Diagnostics Gmbh Use of thiadiazolo[4,3-a]pyridine derivatives

Also Published As

Publication number Publication date
OA12518A (en) 2006-05-29
NO20031482D0 (no) 2003-04-01
JP4177098B2 (ja) 2008-11-05
HUP0301248A2 (hu) 2003-10-28
NZ524852A (en) 2004-09-24
EA007179B1 (ru) 2006-08-25
AU8994501A (en) 2002-04-15
SI1326853T1 (sl) 2005-12-31
ATE304003T1 (de) 2005-09-15
DE60113283T2 (de) 2006-06-08
GT200100196A (es) 2002-07-18
MXPA03002839A (es) 2004-09-10
CA2424279A1 (fr) 2002-04-11
AP2003002764A0 (en) 2003-03-31
KR20030068542A (ko) 2003-08-21
YU24503A (sh) 2006-03-03
KR100614158B1 (ko) 2006-08-21
WO2002028847A1 (fr) 2002-04-11
EA200300333A1 (ru) 2003-10-30
DK1326853T3 (da) 2005-12-12
DZ3440A1 (fr) 2002-04-11
BG107654A (bg) 2003-12-31
HUP0301248A3 (en) 2005-06-28
ECSP034534A (es) 2003-07-25
AR035347A1 (es) 2004-05-12
IL155122A0 (en) 2003-10-31
MA25916A1 (fr) 2003-10-01
HRP20030247A2 (en) 2005-04-30
NO20031482L (no) 2003-04-01
EP1326853A1 (fr) 2003-07-16
US7122565B2 (en) 2006-10-17
US20030045557A1 (en) 2003-03-06
GEP20053459B (en) 2005-02-25
EP1326853B1 (fr) 2005-09-07
BR0114391A (pt) 2003-06-24
DE60113283D1 (de) 2005-10-13
PA8529501A1 (es) 2003-06-30
TNSN01139A1 (en) 2005-11-10
SV2003000633A (es) 2003-04-03
ZA200302346B (en) 2004-08-04
PL366332A1 (en) 2005-01-24
CN1639141A (zh) 2005-07-13
EP1193261A1 (fr) 2002-04-03
ES2247166T3 (es) 2006-03-01
HN2001000217A (es) 2002-06-13
IS6759A (is) 2003-03-27
PT1326853E (pt) 2005-11-30
PE20020419A1 (es) 2002-07-18
JP2004510769A (ja) 2004-04-08
CZ2003857A3 (cs) 2004-02-18
SK3812003A3 (en) 2004-05-04
AU2001289945B2 (en) 2005-12-22
AP1541A (en) 2006-01-11

Similar Documents

Publication Publication Date Title
EE200300134A (et) Uued tiadiasoolid ja oksadiasoolid ning nende kasutamine fosfodiesteraas-7 inhibiitoritena
EE200100373A (et) Bensoheterotsüklid ja nende kasutamine MEK inhibiitoritena
ID30590A (id) Celana sekali pakai jenis-celana pendek
CY2014017I2 (el) Νεες σουλφαμιδες και η χρηση τους σαν ανταγωνιστικων ληπτων ενδοθηλινης
DE60003148D1 (de) Bestimmung der Cachezeit
EE200200715A (et) Asendatud kinasoliini derivaadid ja nende kasutamine inhibiitoritena
EE05169B1 (et) Asendatud oksasolidinoonid ja nende kasutamine
EE200300459A (et) Uued spirotritsüklilised derivaadid ja nende kasutamine fosfodiesteraas-7 inhibiitoritena
EE200200251A (et) Uued N-asabitsükloamiidi derivaadid ja nende kasutamine
NO20023616D0 (no) Ny anvendelse
EE200200286A (et) Uued aminopropüülfosfiinhapped ning nende kasutamine
ATE320242T1 (de) Medizinische aerosolzusammensetzung
DE60106968D1 (de) Kombination von gaba agonisten und sorbitol dehydrogenase inhibitoren
NO20024806D0 (no) Apomorfinderivater samt anvendelse derav
FI20001715A0 (fi) Rankoihin liittyvät järjestelyt ja menetelmät
DE60138280D1 (de) Anpassung des datenalters
EE200100371A (et) Amidinobensüülamiini derivaadid ja nende kasutamine trombiini inhibiitoritena
DE60107074D1 (de) Kristallin form ii von cabergolin
NO20035399D0 (no) Pyrrolidinoksadiazol- og tiadiazolderivater
DE60007360T2 (de) Amorphe modifikation von torasemid
DE60117096D1 (de) Dihydroindol- und tetrahydrochinolinderivate
DE60101245D1 (de) Beschichtungszusammensetzung und ihre Verwendung
NO20031953D0 (no) Anvendelse av disazoforbindelser
ID30381A (id) Penggunaan arilalkanoilpiridazina
NO20025020L (no) Fremstilling av lavsvovelholdig destillater